drugset
drugset / Trial / NCT04715763

INvestigating TELmisartin Study

NCT04715763 ↗

Phase 2 Terminated 24 enrolled University of Hawaii Queen's Medical Center · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.

Timeline

Start
2021-09-01
Primary completion
2022-04-26
Completion
2022-04-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Telmisartan Other / unclassified 80 mg Oral

Indications

COVID-19